Issue Date: 3 August 2016

Subject: REQUEST FOR INFORMATION (RFI) TGF 016-082

Round 1 Questions and Responses

Please note where questions included a company name these have been modified to protect anonymity.

No	Question	Response
1	Can the confidentiality agreement been signed BEFORE we submit the information? Indeed, we would like to have the CDA in place before sharing the confidential information.	Yes we can sign the CDA prior the submission. Please send us the agreement signed, we will send you back the agreement signed by The Global Fund before you submit your proposal.
2	Regarding Schedule C, would it be possible to get the word version of Schedule C to fill in the blank?	We will post the word document on the platform.
3	Regarding a signed copy of submission Schedule B (pdf), please clarify the word "signed". How to make the signed copy? Does supplier need to print it out, sign and submit to the Global Fund? If yes, which part do we sign? What size do we print the document.	Yes you need to print the schedule B, sign each page and upload the scanned version in the Oracle platform. Either A3 either A4 size document is fine.
4	Regarding FPP manufacturers sheet of Schedule B, our company is producing XX (Reference X in the antimalarial list of Global fund) as other formulation (Granules). Is the Global Fund able to add X in the table?	You can add any products which are eligible according to the QA policy: Please indicate this product in the section Other products.
5	For formulators which are also produce/used to produce APIs between 2013 and 2016	In the cell F19 please answer yes and respond to the questions. In case, you do not produce anymore, please indicate in a comment.

No	Question	Response
6	In this sheet, we have noticed the query under section "Commercial Operations" reading as follows: "For Global Fund PPM and AMFm/Co-payment Mechanism business, do you produce artemisinin API for your own need partially or completely?" – Against this when we select "No" from the drop down, we are directed to answer questions in column Q to AB and we are advised to ignore the Questions below. In columns Q to AB, the details are to be provided relating to our artemisinin API suppliers and the respective volume purchased from each of them (in kg for confirmed POs) We do not purchase Artemisinin, we purchase only Artemether from our suppliers. Please confirm whether we have to provide details of purchase of Artemether in these columns. Secondly, in the above question you have also asked us to give the volume purchased from each supplier in Kgs for confirmed PO's. – What exactly do you mean by confirmed PO's. Do you mean, each PO confirmed for AMFm supplies and also for each PO confirmed for PPM supplies. Kindly note that we do not purchase the API on the basis of each PO, but we always keep a stock of API required for production for three months and as and when we start using the stock, we procure equivalent quantity to replenish the stocks. In such a case, how do we give the details if you want the volume purchase against each PO.	In case you do not have any commercial arrangement with artemisinin, you do not need to indicate any information related to Arthemether. In addition, in case you have any technical constraints which have a consequence to use certain artemisinin quality/suppliers. Please let us know. You do not need to indicate the volumes purchased for each PO but the volumes purchased (including your safety stock) for the total amount of the PO confirmed for AMFm and PPM for the calendar year.